Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dongkoo Bio & Pharma Co., Ltd. (006620:KRX), powered by AI.
Dongkoo Bio & Pharma Co., Ltd. is currently trading at ₩5,240. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Dongkoo Bio & Pharma Co., Ltd. on Alpha Lenz.
Dongkoo Bio & Pharma Co., Ltd.'s P/E ratio is 70.3.
“Dongkoo Bio & Pharma Co., Ltd. trades at a P/E of 70.3 (premium valuation) with modest ROE of 1.9%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.”
Ask for details →Dongkoo Bio & Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on developing and manufacturing a broad range of healthcare products. This company is primarily dedicated to advancing medical treatments and enhancing health outcomes through its robust portfolio of prescription and over-the-counter medications. Dongkoo Bio & Pharma impacts various sectors including dermatology, oncology, and gastroenterology, providing specialized solutions that cater to both domestic and international markets. As an integral player in the health care sector, the company leverages cutting-edge research and development to drive innovation and meet emerging medical needs. Dongkoo Bio & Pharma's commitment to quality and safety reinforces its role as a significant contributor to public health, enhancing lives by offering accessible and effective pharmaceutical products. Through strategic collaborations and continuous product development, the company holds a prominent position in enhancing the global pharmaceutical landscape.
“Dongkoo Bio & Pharma Co., Ltd. trades at a P/E of 70.3 (premium valuation) with modest ROE of 1.9%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.”
Ask for details →Dongkoo Bio & Pharma Co., Ltd. (ticker: 006620) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $149.2B.
The current price is ₩5,240 with a P/E ratio of 70.3x and P/B of 1.36x.
ROE is 1.89% and operating margin is 5.09%. Annual revenue is $249.3B.